Asenapine vs Paliperidone (Invega)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Asenapine

Marketed by AbbVie and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT00212784 · Phase 3 · completed

This 52-week trial randomly assigned 1,225 people with schizophrenia to asenapine or to olanzapine, with participants, carers, investigators and outcome assessors all unaware of assignment. The primary measure was change in total PANSS symptom score. Asenapine improved symptoms by 21.0 points against 27.5 points for olanzapine, a difference favouring olanzapine at p<0.0001, so asenapine was less effective than its active comparator on this measure.

Reported efficacy

Change in total PANSS score at endpoint (Screening, Week 76, 100, and once every 24 weeks thereafter until endpoint): Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint (unclear)

Result source: NCT00212771

Paliperidone (Invega)

Marketed by Johnson & Johnson

Approved in Schizophreniasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: September 2027 · NCT04478838 (registry estimate)

Reported efficacy

Number of Participants With Relapse (Up to Day 730); Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Up to Day 730): Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 (not_applicable)

Result source: NCT04072575

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAsenapinePaliperidone (Invega)
PANSS total, change-25.5 vs -17.8−7.7 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
18 other results
  • -21.7 vs -16.2 5 mg BID · wk 6 · n 111 · Phase 3 · primary NCT01617187
  • -12.2 vs -0.9 5 mg BID · wk 6 · n 173 · Phase 3 · primary NCT01098110
  • -14.2 vs -0.9 10 mg BID · wk 6 · n 178 · Phase 3 · primary NCT01098110
  • -23.7 vs -17.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · primary NCT01190254
  • -17.4 vs -16.2 2.5 mg BID · wk 6 · n 96 · Phase 3 · primary NCT01617187
  • -19 vs -15.4 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -17.1 vs -15.5 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -14.8 vs -13.2 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -12.5 vs -10.7 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -9.1 vs -7.1 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -4.9 vs -4.8 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -17 vs -15.4 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -12.3 vs -15.5 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -12 vs -13.2 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -9.9 vs -10.7 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -7.2 vs -7.1 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -4 vs -4.8 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
  • -21 vs -27.5 wk 52 · Phase 3 · primary NCT00212784
-9.8 vs -7.9−1.9 vs placebowk 6 · n 54NCT00518323
8 other results
  • -17.3 vs -7.9 wk 6 · n 48 · Phase 3 · primary NCT00518323
  • -13.8 vs -7.9 wk 6 · n 47 · Phase 3 · primary NCT00518323
  • -9.1 vs 3.8 wk 6 · n 134 · Phase 3 · primary NCT00396565
  • -19.3 vs -19.8 wk 8 · n 112 · Phase 3 · primary NCT01009047
  • -13.5 vs -16.6 wk 24 · n 234 · Phase 3 · secondary NCT00645099
  • -25.6 vs -26.8 wk 26 · n 112 · Phase 3 · secondary NCT01009047
  • -15 vs -11.7 6 mg · wk 6 · n 70 · Phase 4 · primary NCT00524043
  • -8.9 vs -11.7 1.5 mg · wk 6 · n 66 · Phase 4 · primary NCT00524043
CGI-S, change-1.3 vs -0.8−0.5 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
17 other results
  • -1.2 vs -1 5 mg BID · wk 6 · n 111 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.2 5 mg BID · wk 6 · n 173 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.7 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -0.2 vs -0.2 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.2 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · secondary NCT01190254
  • -0.9 vs -1 2.5 mg BID · wk 6 · n 96 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.8 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.7 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -0.1 vs -0.2 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
0 vs 0±0 vs placebowk 6 · n 54NCT00518323
7 other results
  • -1 vs 0 wk 6 · n 48 · Phase 3 · secondary NCT00518323
  • -1 vs 0 wk 6 · n 47 · Phase 3 · secondary NCT00518323
  • -0.4 vs 0.2 wk 6 · n 134 · Phase 3 · secondary NCT00396565
  • -1 vs -1 wk 8 · n 112 · Phase 3 · secondary NCT01009047
  • -1 vs -1 wk 26 · n 112 · Phase 3 · secondary NCT01009047
  • -0.5 vs -1 6 mg · wk 6 · n 70 · Phase 4 · secondary NCT00524043
  • 0 vs -1 1.5 mg · wk 6 · n 66 · Phase 4 · secondary NCT00524043
PANSS response39.3% vs 20.7%+18.6 vs placebo5 mg BID · wk 6 · n 173NCT01098110
1 other result
  • 43.8% vs 20.7% 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
76.8% vs 81.6%vs Aripiprazolewk 26 · n 112NCT01009047
1 other result
  • 67.9% vs 76.3% wk 8 · n 112 · Phase 3 · secondary NCT01009047
PSP, change—Not posted · NCT0021277117.1 vs 17.1vs Aripiprazolewk 26 · n 112NCT01009047
3 other results
  • 12.2 vs 12.2 wk 8 · n 112 · Phase 3 · secondary NCT01009047
  • 5.7 vs 1.6 6 mg · wk 6 · n 70 · Phase 4 · secondary NCT00524043
  • 2.9 vs 1.6 1.5 mg · wk 6 · n 66 · Phase 4 · secondary NCT00524043
Relapse (% of patients)—Not posted · NCT00212771—Not posted · NCT03485417

PANSS total, change

Asenapine
-25.5 vs -17.8−7.7 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
18 other results
  • -21.7 vs -16.2 5 mg BID · wk 6 · n 111 · Phase 3 · primary NCT01617187
  • -12.2 vs -0.9 5 mg BID · wk 6 · n 173 · Phase 3 · primary NCT01098110
  • -14.2 vs -0.9 10 mg BID · wk 6 · n 178 · Phase 3 · primary NCT01098110
  • -23.7 vs -17.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · primary NCT01190254
  • -17.4 vs -16.2 2.5 mg BID · wk 6 · n 96 · Phase 3 · primary NCT01617187
  • -19 vs -15.4 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -17.1 vs -15.5 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -14.8 vs -13.2 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -12.5 vs -10.7 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -9.1 vs -7.1 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -4.9 vs -4.8 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -17 vs -15.4 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -12.3 vs -15.5 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -12 vs -13.2 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -9.9 vs -10.7 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -7.2 vs -7.1 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -4 vs -4.8 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
  • -21 vs -27.5 wk 52 · Phase 3 · primary NCT00212784
Paliperidone (Invega)
-9.8 vs -7.9−1.9 vs placebowk 6 · n 54NCT00518323
8 other results
  • -17.3 vs -7.9 wk 6 · n 48 · Phase 3 · primary NCT00518323
  • -13.8 vs -7.9 wk 6 · n 47 · Phase 3 · primary NCT00518323
  • -9.1 vs 3.8 wk 6 · n 134 · Phase 3 · primary NCT00396565
  • -19.3 vs -19.8 wk 8 · n 112 · Phase 3 · primary NCT01009047
  • -13.5 vs -16.6 wk 24 · n 234 · Phase 3 · secondary NCT00645099
  • -25.6 vs -26.8 wk 26 · n 112 · Phase 3 · secondary NCT01009047
  • -15 vs -11.7 6 mg · wk 6 · n 70 · Phase 4 · primary NCT00524043
  • -8.9 vs -11.7 1.5 mg · wk 6 · n 66 · Phase 4 · primary NCT00524043

CGI-S, change

Asenapine
-1.3 vs -0.8−0.5 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
17 other results
  • -1.2 vs -1 5 mg BID · wk 6 · n 111 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.2 5 mg BID · wk 6 · n 173 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.7 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -0.2 vs -0.2 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.2 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · secondary NCT01190254
  • -0.9 vs -1 2.5 mg BID · wk 6 · n 96 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.8 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.7 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -0.1 vs -0.2 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
Paliperidone (Invega)
0 vs 0±0 vs placebowk 6 · n 54NCT00518323
7 other results
  • -1 vs 0 wk 6 · n 48 · Phase 3 · secondary NCT00518323
  • -1 vs 0 wk 6 · n 47 · Phase 3 · secondary NCT00518323
  • -0.4 vs 0.2 wk 6 · n 134 · Phase 3 · secondary NCT00396565
  • -1 vs -1 wk 8 · n 112 · Phase 3 · secondary NCT01009047
  • -1 vs -1 wk 26 · n 112 · Phase 3 · secondary NCT01009047
  • -0.5 vs -1 6 mg · wk 6 · n 70 · Phase 4 · secondary NCT00524043
  • 0 vs -1 1.5 mg · wk 6 · n 66 · Phase 4 · secondary NCT00524043

PANSS response

Asenapine
39.3% vs 20.7%+18.6 vs placebo5 mg BID · wk 6 · n 173NCT01098110
1 other result
  • 43.8% vs 20.7% 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
Paliperidone (Invega)
76.8% vs 81.6%vs Aripiprazolewk 26 · n 112NCT01009047
1 other result
  • 67.9% vs 76.3% wk 8 · n 112 · Phase 3 · secondary NCT01009047

PSP, change

Asenapine
—Not posted · NCT00212771
Paliperidone (Invega)
17.1 vs 17.1vs Aripiprazolewk 26 · n 112NCT01009047
3 other results
  • 12.2 vs 12.2 wk 8 · n 112 · Phase 3 · secondary NCT01009047
  • 5.7 vs 1.6 6 mg · wk 6 · n 70 · Phase 4 · secondary NCT00524043
  • 2.9 vs 1.6 1.5 mg · wk 6 · n 66 · Phase 4 · secondary NCT00524043

Relapse (% of patients)

Asenapine
—Not posted · NCT00212771
Paliperidone (Invega)
—Not posted · NCT03485417
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
8 other shared endpoints and safety

Coverage. Asenapine: 12 of 12 rows · Paliperidone (Invega): 12 of 12 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAsenapine
Rows use multiple source trials
Paliperidone (Invega)
Rows use multiple source trials
CGAS
absolute change · score
15 vs 10.2 placebo score @ 8wk5.0 mg BIDa,b,c,d
NCT01190254 · Phase 3 · registry result, not featured evidence
show 1 more dose
12.8 vs 10.2 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
8.6 vs 5 placebo score @ 6wka,b,c,d
NCT00518323 · Phase 3 · registry result, not featured evidence
show 2 more doses
4.4 vs 5 placebo score @ 6wk
NCT00518323 · Phase 3 · registry result, not featured evidence
13.1 vs 5 placebo score @ 6wk
NCT00518323 · Phase 3 · registry result, not featured evidence
PANSS 30%
responder rate · % of participants
25.2% (n=111) vs 19.2% (n=99) placebo @ 6wk5 mg BIDa,b,c
NCT01617187 · Phase 3 · registry result, not featured evidence
show 1 more dose
14.6% (n=96) vs 19.2% (n=99) placebo @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
25.4% (n=134) vs 9.4% (n=138) placebo @ 6wkb,c
NCT00396565 · Phase 3 · registry result, not featured evidence
PANSS General Psychopathology
absolute change · score
-10.1 vs -8 placebo score @ 6wk5 mg BIDa,b,c
NCT01617187 · Phase 3 · registry result, not featured evidence
show 1 more dose
-8.9 vs -8 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.1 vs 2.2 placebo score @ 6wkb,c
NCT00396565 · Phase 3 · registry result, not featured evidence
PANSS Marder Negative
absolute change · score
-5.3 vs -3.7 placebo score @ 8wk5.0 mg BIDa,b,c
NCT01190254 · Phase 3 · registry result, not featured evidence
show 1 more dose
-5.2 vs -3.7 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-4.3 vs -4.7 Aripiprazole score @ 8wkb,c
NCT01009047 · Phase 3 · registry result, not featured evidence
PANSS Negative Subscale
absolute change · score
-4.9 vs -3.4 placebo score @ 8wk5.0 mg BIDa,b,c,d
NCT01190254 · Phase 3 · registry result, not featured evidence
show 1 more dose
-4.8 vs -3.4 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-2.4 vs 0 placebo score @ 6wkb,c,d
NCT00396565 · Phase 3 · registry result, not featured evidence
PANSS Positive Subscale
absolute change · score
-9.1 vs -6 placebo score @ 8wk5.0 mg BIDa,b,c,d
NCT01190254 · Phase 3 · registry result, not featured evidence
show 1 more dose
-7.9 vs -6 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-2.6 vs 1.6 placebo score @ 6wkb,c,d
NCT00396565 · Phase 3 · registry result, not featured evidence
PANSS Total
absolute change · score
No placebo or comparator arm
-11.08 score @ 52wka,b,c
NCT01244828 · Phase 3 · registry result, not featured evidence
show 1 more dose
-5.48 score
NCT01244828 · Phase 3 · registry result, not featured evidence
-12.6 score @ 104wka,b,c
NCT00488319 · Phase 3 · registry result, not featured evidence
show 2 more doses
-22.4 score @ 104wk
NCT00488319 · Phase 3 · registry result, not featured evidence
-18.9 score @ 104wk
NCT00488319 · Phase 3 · registry result, not featured evidence
Weight
absolute change · kg
0 vs 2.6 Olanzapine kg @ 26wkb,c,e
NCT00145496 · Phase 3 · registry result, not featured evidence
1.16 vs 3.81 Olanzapine kg @ 24wkb,c,e
NCT00645099 · Phase 3 · registry result, not featured evidence
Dropout rate
44.4%5 mg twice dailyf
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
16.7%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
54.8%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
0%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
1%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
49.7%
NCT01244828 · Phase 3 · registry result, not featured evidence
35.2%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
40.1%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
50%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
20.9%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
20.8%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
17.3%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
33.7%
NCT00174265 · Phase 3 · registry result, not featured evidence
50.4%
NCT00145496 · Phase 3 · registry result, not featured evidence
30.4%
NCT00150176 · Phase 3 · registry result, not featured evidence
15.7%
NCT00265343 · Phase 3 · registry result, not featured evidence
67.7%
NCT00156065 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
33.3%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
25%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
41.2%f
NCT00784238 · Phase 4 · registry result, not featured evidence
show 35 more results
48.4%
NCT00761579 · Phase 4 · registry result, not featured evidence
36.4%
NCT00761605 · Phase 4 · registry result, not featured evidence
20%
NCT01387542 · Phase 4 · registry result, not featured evidence
11.3%
NCT01362439 · Phase 4 · registry result, not featured evidence
—Paliperidone ER - Extension Phase
NCT01010776 · Phase 4 · registry result, not featured evidence
—Paliperidone ER - Main Phase
NCT01010776 · Phase 4 · registry result, not featured evidence
32.6%
NCT01724359 · Phase 4 · registry result, not featured evidence
27.1%
NCT01577186 · Phase 4 · registry result, not featured evidence
40.5%
NCT00757705 · Phase 4 · registry result, not featured evidence
27.8%
NCT01577160 · Phase 4 · registry result, not featured evidence
—Paliperidone ER Phase
NCT00535145 · Phase 4 · registry result, not featured evidence
25.4%Study Treatment
NCT00535145 · Phase 4 · registry result, not featured evidence
—TAU - Pali ER
NCT00535145 · Phase 4 · registry result, not featured evidence
40%6 mg
NCT00524043 · Phase 4 · registry result, not featured evidence
47%1.5 mg
NCT00524043 · Phase 4 · registry result, not featured evidence
0%PALI ER Delayed Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
0%PALI ER Immediate Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
—Paliperidone DB/Paliperidone Open-
NCT01662310 · Phase 3 · registry result, not featured evidence
—Paliperidone: Double Blind (DB) Ph
NCT01662310 · Phase 3 · registry result, not featured evidence
36.4%Paliperidone (Double-blind)/Palipe
NCT00488319 · Phase 3 · registry result, not featured evidence
50.2%Paliperidone (No Double-blind)/Pal
NCT00488319 · Phase 3 · registry result, not featured evidence
38.5%Placebo/Paliperidone
NCT00488319 · Phase 3 · registry result, not featured evidence
24.8%
NCT01009047 · Phase 3 · registry result, not featured evidence
19.1%
NCT01541371 · Phase 3 · registry result, not featured evidence
50%
NCT00473434 · Phase 3 · registry result, not featured evidence
20.4%
NCT00566631 · Phase 3 · registry result, not featured evidence
—
NCT00645099 · Phase 3 · registry result, not featured evidence
28.3%Paliperidone ER: Lack of Efficacy
NCT01662648 · Phase 3 · registry result, not featured evidence
29.8%Paliperidone ER: Lack of Tolerabil
NCT01662648 · Phase 3 · registry result, not featured evidence
22.9%Pali ER High
NCT00518323 · Phase 3 · registry result, not featured evidence
35.2%Pali ER Low
NCT00518323 · Phase 3 · registry result, not featured evidence
16.7%Pali ER Medium
NCT00518323 · Phase 3 · registry result, not featured evidence
15.4%
NCT01606228 · Phase 3 · registry result, not featured evidence
45.4%
NCT01561898 · Phase 3 · registry result, not featured evidence
35.3%
NCT00396565 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
22.2%5 mg twice dailyf
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
0%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
22.3%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
0%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
0%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
23.6%
NCT01244828 · Phase 3 · registry result, not featured evidence
17%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
17.6%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
0%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
5.1%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
7.5%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
6.1%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
8.1%
NCT00174265 · Phase 3 · registry result, not featured evidence
17.2%
NCT00145496 · Phase 3 · registry result, not featured evidence
8.2%
NCT00150176 · Phase 3 · registry result, not featured evidence
7.5%
NCT00265343 · Phase 3 · registry result, not featured evidence
11.8%
NCT00156065 · Phase 3 · registry result, not featured evidence
—5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
4.8%f
NCT00784238 · Phase 4 · registry result, not featured evidence
show 35 more results
5.3%
NCT00761579 · Phase 4 · registry result, not featured evidence
6.7%
NCT00761605 · Phase 4 · registry result, not featured evidence
7.5%
NCT01387542 · Phase 4 · registry result, not featured evidence
0.8%
NCT01362439 · Phase 4 · registry result, not featured evidence
—Paliperidone ER - Extension Phase
NCT01010776 · Phase 4 · registry result, not featured evidence
—Paliperidone ER - Main Phase
NCT01010776 · Phase 4 · registry result, not featured evidence
10.5%
NCT01724359 · Phase 4 · registry result, not featured evidence
4.8%
NCT01577186 · Phase 4 · registry result, not featured evidence
6.4%
NCT00757705 · Phase 4 · registry result, not featured evidence
2.5%
NCT01577160 · Phase 4 · registry result, not featured evidence
—Paliperidone ER Phase
NCT00535145 · Phase 4 · registry result, not featured evidence
2.6%Study Treatment
NCT00535145 · Phase 4 · registry result, not featured evidence
—TAU - Pali ER
NCT00535145 · Phase 4 · registry result, not featured evidence
2.9%6 mg
NCT00524043 · Phase 4 · registry result, not featured evidence
10.6%1.5 mg
NCT00524043 · Phase 4 · registry result, not featured evidence
—PALI ER Delayed Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
—PALI ER Immediate Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
—Paliperidone DB/Paliperidone Open-
NCT01662310 · Phase 3 · registry result, not featured evidence
—Paliperidone: Double Blind (DB) Ph
NCT01662310 · Phase 3 · registry result, not featured evidence
1.7%Paliperidone (Double-blind)/Palipe
NCT00488319 · Phase 3 · registry result, not featured evidence
9.5%Paliperidone (No Double-blind)/Pal
NCT00488319 · Phase 3 · registry result, not featured evidence
2.6%Placebo/Paliperidone
NCT00488319 · Phase 3 · registry result, not featured evidence
4.4%
NCT01009047 · Phase 3 · registry result, not featured evidence
3.7%
NCT01541371 · Phase 3 · registry result, not featured evidence
4.7%
NCT00473434 · Phase 3 · registry result, not featured evidence
3.1%
NCT00566631 · Phase 3 · registry result, not featured evidence
—
NCT00645099 · Phase 3 · registry result, not featured evidence
8.3%Paliperidone ER: Lack of Efficacy
NCT01662648 · Phase 3 · registry result, not featured evidence
6.2%Paliperidone ER: Lack of Tolerabil
NCT01662648 · Phase 3 · registry result, not featured evidence
2.1%Pali ER High
NCT00518323 · Phase 3 · registry result, not featured evidence
1.9%Pali ER Low
NCT00518323 · Phase 3 · registry result, not featured evidence
2.1%Pali ER Medium
NCT00518323 · Phase 3 · registry result, not featured evidence
0.5%
NCT01606228 · Phase 3 · registry result, not featured evidence
14.4%
NCT01561898 · Phase 3 · registry result, not featured evidence
3.7%
NCT00396565 · Phase 3 · registry result, not featured evidence
Serious AEs
0%5 mg twice dailyf
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
0%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
20.4%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
4.4%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.2%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
8.9%
NCT01244828 · Phase 3 · registry result, not featured evidence
5.7%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
2.8%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
12.5%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
3.6%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
2.8%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
3.1%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
4.7%
NCT00174265 · Phase 3 · registry result, not featured evidence
12.3%
NCT00145496 · Phase 3 · registry result, not featured evidence
3.1%
NCT00150176 · Phase 3 · registry result, not featured evidence
6.7%
NCT00265343 · Phase 3 · registry result, not featured evidence
14.1%
NCT00156065 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
7.3%f
NCT00784238 · Phase 4 · registry result, not featured evidence
show 35 more results
12.1%
NCT00761579 · Phase 4 · registry result, not featured evidence
9.8%
NCT00761605 · Phase 4 · registry result, not featured evidence
2.5%
NCT01387542 · Phase 4 · registry result, not featured evidence
0.8%
NCT01362439 · Phase 4 · registry result, not featured evidence
1.9%Paliperidone ER - Extension Phase
NCT01010776 · Phase 4 · registry result, not featured evidence
6.5%Paliperidone ER - Main Phase
NCT01010776 · Phase 4 · registry result, not featured evidence
7.4%
NCT01724359 · Phase 4 · registry result, not featured evidence
7.7%
NCT01577186 · Phase 4 · registry result, not featured evidence
3.7%
NCT00757705 · Phase 4 · registry result, not featured evidence
0%
NCT01577160 · Phase 4 · registry result, not featured evidence
2.4%Paliperidone ER Phase
NCT00535145 · Phase 4 · registry result, not featured evidence
—Study Treatment
NCT00535145 · Phase 4 · registry result, not featured evidence
0%TAU - Pali ER
NCT00535145 · Phase 4 · registry result, not featured evidence
7.1%6 mg
NCT00524043 · Phase 4 · registry result, not featured evidence
10.6%1.5 mg
NCT00524043 · Phase 4 · registry result, not featured evidence
4%PALI ER Delayed Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
3.1%PALI ER Immediate Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
4.3%Paliperidone DB/Paliperidone Open-
NCT01662310 · Phase 3 · registry result, not featured evidence
3.1%Paliperidone: Double Blind (DB) Ph
NCT01662310 · Phase 3 · registry result, not featured evidence
3.4%Paliperidone (Double-blind)/Palipe
NCT00488319 · Phase 3 · registry result, not featured evidence
18.9%Paliperidone (No Double-blind)/Pal
NCT00488319 · Phase 3 · registry result, not featured evidence
23.1%Placebo/Paliperidone
NCT00488319 · Phase 3 · registry result, not featured evidence
6.2%
NCT01009047 · Phase 3 · registry result, not featured evidence
0.2%
NCT01541371 · Phase 3 · registry result, not featured evidence
42.2%
NCT00473434 · Phase 3 · registry result, not featured evidence
7.8%
NCT00566631 · Phase 3 · registry result, not featured evidence
8.8%
NCT00645099 · Phase 3 · registry result, not featured evidence
6.8%Paliperidone ER: Lack of Efficacy
NCT01662648 · Phase 3 · registry result, not featured evidence
4.9%Paliperidone ER: Lack of Tolerabil
NCT01662648 · Phase 3 · registry result, not featured evidence
2.1%Pali ER High
NCT00518323 · Phase 3 · registry result, not featured evidence
3.7%Pali ER Low
NCT00518323 · Phase 3 · registry result, not featured evidence
2.1%Pali ER Medium
NCT00518323 · Phase 3 · registry result, not featured evidence
2.1%
NCT01606228 · Phase 3 · registry result, not featured evidence
—
NCT01561898 · Phase 3 · registry result, not featured evidence
3%
NCT00396565 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
5 mg twice dailyf
daytime drowsiness 22.2%
NCT01549041 · Phase 4 · registry result, not featured evidence
show 19 more results
10 mg daily in the evening
daytime drowsiness 0%
NCT01549041 · Phase 4 · registry result, not featured evidence
5/10 mg BID
nasopharyngitis 21.7%
schizophrenia 10.8%
somnolence 10.8%
NCT01142596 · Phase 3 · registry result, not featured evidence
5 mg BID
insomnia 15% (placebo 13.9%)
headache 8.8% (placebo 2%)
anxiety 7.1% (placebo 11.9%)
NCT01617187 · Phase 3 · registry result, not featured evidence
2.5 mg BID
headache 10.3% (placebo 2%)
insomnia 9.3% (placebo 13.9%)
anxiety 7.2% (placebo 11.9%)
NCT01617187 · Phase 3 · registry result, not featured evidence
nasopharyngitis 21%
somnolence 12.7%
weight increased 12.7%
NCT01244828 · Phase 3 · registry result, not featured evidence
5 mg BID
akathisia 11.4% (placebo 5.2%)
hypoaesthesia oral 10.9% (placebo 3.4%)
insomnia 9.7% (placebo 12.1%)
NCT01098110 · Phase 3 · registry result, not featured evidence
10 mg BID
schizophrenia 13.8% (placebo 24.1%)
somnolence 12.2% (placebo 1.7%)
akathisia 10.5% (placebo 5.2%)
NCT01098110 · Phase 3 · registry result, not featured evidence
accidental overdose 12.5%
acne 12.5%
akathisia 12.5%
NCT01190267 · Phase 3 · registry result, not featured evidence
somnolence 14.8%
headache 6.6%
sedation 5.1%
NCT01190267 · Phase 3 · registry result, not featured evidence
5.0 mg BID
somnolence 17% (placebo 6.9%)
sedation 11.3% (placebo 2%)
insomnia 9.4% (placebo 5.9%)
NCT01190254 · Phase 3 · registry result, not featured evidence
2.5 mg BID
somnolence 20.4% (placebo 6.9%)
dizziness 7.1% (placebo 1%)
headache 7.1% (placebo 5.9%)
NCT01190254 · Phase 3 · registry result, not featured evidence
insomnia 10.6%
weight increased 5.9%
headache 2.4%
NCT00174265 · Phase 3 · registry result, not featured evidence
insomnia 17.6%
somnolence 14.8%
headache 13.5%
NCT00145496 · Phase 3 · registry result, not featured evidence
insomnia 20.1% (placebo 24.5%)
somnolence 16% (placebo 17.2%)
weight increased 14.4% (placebo 10.9%)
NCT00150176 · Phase 3 · registry result, not featured evidence
headache 5.2%
influenza 5.2%
schizophrenia 5.2%
NCT00265343 · Phase 3 · registry result, not featured evidence
insomnia 18.5%
headache 10.9%
parkinsonism 10.9%
NCT00156065 · Phase 3 · registry result, not featured evidence
5 mg
dystonia 66.7%
dizziness 33.3%
nausea 33.3%
NCT01206517 · Phase 1 · registry result, not featured evidence
10 mg
hypoaesthesia oral 50%
dizziness 38.9%
dysgeusia 38.9%
NCT01206517 · Phase 1 · registry result, not featured evidence
2.5 mg
sedation 33.3%
dysgeusia 16.7%
hypoaesthesia oral 16.7%
NCT01206517 · Phase 1 · registry result, not featured evidence
f
akathisia 8.3%
extrapyramidal disorder 4.8%
insomnia 4.8%
NCT00784238 · Phase 4 · registry result, not featured evidence
show 33 more results
akathisia 18.4%
weight increased 15.3%
muscle rigidity 7.4%
NCT00761579 · Phase 4 · registry result, not featured evidence
insomnia 12.4%
akathisia 11.4%
weight increased 9.3%
NCT00761605 · Phase 4 · registry result, not featured evidence
drowsiness 15%
headache 15%
insomnia 12.5%
NCT01387542 · Phase 4 · registry result, not featured evidence
insomnia 3%
weight increase 3%
extrapyramidal symptoms 2.3%
NCT01362439 · Phase 4 · registry result, not featured evidence
weight increased 12.6%
insomnia 8.8%
depression 4.4%
NCT01010776 · Phase 4 · registry result, not featured evidence
insomnia 14.9%
anxiety 10.7%
weight increased 10.7%
NCT01010776 · Phase 4 · registry result, not featured evidence
insomnia 25.3%
akathisia 23.2%
parkinsonism 15.8%
NCT01724359 · Phase 4 · registry result, not featured evidence
extrapyramidal disorder 11.7%
upper respiratory tract infection 6.7%
tremor 4.8%
NCT01577186 · Phase 4 · registry result, not featured evidence
insomnia 20.7%
extrapyramidal disorder 13.7%
anxiety 11.7%
NCT00757705 · Phase 4 · registry result, not featured evidence
insomnia 15.9%
constipation 11.3%
extrapyramidal disorder 9.6%
NCT01577160 · Phase 4 · registry result, not featured evidence
tremor 8.3%
headache 7.1%
nausea 6%
NCT00535145 · Phase 4 · registry result, not featured evidence
weight increased 6%
headache 3.6%
akathisia 2.4%
NCT00535145 · Phase 4 · registry result, not featured evidence
6 mg
headache 11.4% (placebo 15.6%)
insomnia 10% (placebo 9.4%)
tremor 10% (placebo 3.1%)
NCT00524043 · Phase 4 · registry result, not featured evidence
1.5 mg
insomnia 13.6% (placebo 9.4%)
dizziness 7.6% (placebo 1.6%)
headache 7.6% (placebo 15.6%)
NCT00524043 · Phase 4 · registry result, not featured evidence
constipation 9.1%
insomnia 9.1%
somnolence 8.1%
NCT00535132 · Phase 4 · registry result, not featured evidence
insomnia 9.2%
headache 8.2%
constipation 6.1%
NCT00535132 · Phase 4 · registry result, not featured evidence
constipation 4.3% (placebo 3.4%)
akathisia 2.1% (placebo 5.1%)
headache 2.1% (placebo 1.7%)
NCT01662310 · Phase 3 · registry result, not featured evidence
akathisia 4.7% (placebo 5.1%)
nausea 3.1% (placebo 0%)
tremor 3.1% (placebo 0%)
NCT01662310 · Phase 3 · registry result, not featured evidence
nasopharyngitis 15.3%
somnolence 15.3%
tremor 10.2%
NCT00488319 · Phase 3 · registry result, not featured evidence
weight increased 24.3%
headache 18.9%
somnolence 18.5%
NCT00488319 · Phase 3 · registry result, not featured evidence
somnolence 25.6%
insomnia 17.9%
anxiety 10.3%
NCT00488319 · Phase 3 · registry result, not featured evidence
akathisia 11.5%
headache 10.6%
somnolence 10.6%
NCT01009047 · Phase 3 · registry result, not featured evidence
akathisia 18.4%
tremor 12.9%
dystonia 8.7%
NCT01541371 · Phase 3 · registry result, not featured evidence
insomnia 15.6%
headache 10.9%
akathisia 9.4%
NCT00473434 · Phase 3 · registry result, not featured evidence
insomnia 23.1%
tachycardia 8.5%
headache 7.5%
NCT00566631 · Phase 3 · registry result, not featured evidence
insomnia 9.6%
weight increased 9.6%
headache 4.6%
NCT00645099 · Phase 3 · registry result, not featured evidence
insomnia 9.8%
extrapyramidal disorder 6.6%
headache 4.5%
NCT01662648 · Phase 3 · registry result, not featured evidence
insomnia 11.6%
headache 4.1%
nausea 3.9%
NCT01662648 · Phase 3 · registry result, not featured evidence
somnolence 20.8% (placebo 2%)
akathisia 16.7% (placebo 0%)
insomnia 12.5% (placebo 21.6%)
NCT00518323 · Phase 3 · registry result, not featured evidence
headache 9.3% (placebo 3.9%)
insomnia 9.3% (placebo 21.6%)
schizophrenia 9.3% (placebo 7.8%)
NCT00518323 · Phase 3 · registry result, not featured evidence
somnolence 14.6% (placebo 2%)
akathisia 8.3% (placebo 0%)
tremor 8.3% (placebo 0%)
NCT00518323 · Phase 3 · registry result, not featured evidence
insomnia 13.3%
anemia 4.8%
acute psychotic symptoms 1.6%
NCT01606228 · Phase 3 · registry result, not featured evidence
schizophrenia 16.4% (placebo 42.8%)
insomnia 11.2% (placebo 10.1%)
nasopharyngitis 10.4% (placebo 8%)
NCT00396565 · Phase 3 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 8 weeks versus 6 weeks.
  5. eAssessment timepoints differ: 26 weeks versus 24 weeks.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Asenapine

BPRS Total 7.72 score @ 2wk5 mg twice daily
absolute change · score
No placebo or comparator arm
NCT01549041 · Phase 4 · registry result, not featured evidence
show 1 more result
16.08 score @ 2wk10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
Time to Loss of Efficacy 5.82 months5/10 mg BID
time to event · months
Extension (open-label)
No placebo or comparator arm
NCT01142596 · Phase 3 · registry result, not featured evidence · converted to months from 177 days as posted
show 1 more result
12.09 months*5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence · converted to months from 368 days as posted
CGI-I 33.3% (n=111) vs 37.8% (n=99) placebo @ 0.57wk5 mg BID
responder rate · % of participants
NCT01617187 · Phase 3 · registry result, not featured evidence
show 19 more results
46.8% (n=111) vs 45.5% (n=99) placebo @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
60.4% (n=111) vs 54.5% (n=99) placebo @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
63.1% (n=111) vs 58.6% (n=99) placebo @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
62.2% (n=111) vs 60.6% (n=99) placebo @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
64% (n=111) vs 64.6% (n=99) placebo @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
66.7% (n=111) vs 62.6% (n=99) placebo @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
63.6% (n=173) vs 41.4% (n=174) placebo @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
39.4% (n=104) vs 28% (n=100) placebo @ 8wk*5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence · converted to % from 41 participants as posted
60.1% (n=104) vs 54.7% (n=100) placebo @ 8.3wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
70.2% (n=178) vs 41.4% (n=174) placebo @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
34.7% (n=96) vs 37.8% (n=99) placebo @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
51% (n=96) vs 45.5% (n=99) placebo @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
51% (n=96) vs 54.5% (n=99) placebo @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
54.2% (n=96) vs 58.6% (n=99) placebo @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
58.3% (n=96) vs 60.6% (n=99) placebo @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
60.4% (n=96) vs 64.6% (n=99) placebo @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
59.4% (n=96) vs 62.6% (n=99) placebo @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
37.5% (n=96) vs 28% (n=100) placebo @ 8wk*2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence · converted to % from 36 participants as posted
47.1% (n=96) vs 54.7% (n=100) placebo @ 8.3wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Negative -0.5 vs -0.8 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 15 more results
-1.3 vs -1.1 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -1.8 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.3 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.1 vs -3 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.4 vs -2.6 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.3 vs -3.2 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.72 vs -0.24 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-3.27 vs -0.24 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-0.7 vs -0.8 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.2 vs -1.1 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.6 vs -1.8 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -2.3 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -3 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.3 vs -2.6 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.3 vs -3.2 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
PANSS Positive -1.6 vs -1.7 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 15 more results
-2.8 vs -2.6 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.9 vs -3.7 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5 vs -4.5 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.7 vs -5 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.3 vs -5.5 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.2 vs -5.4 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.31 vs -0.85 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-4.63 vs -0.85 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-1.2 vs -1.7 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -2.6 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.4 vs -3.7 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4 vs -4.5 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.1 vs -5 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.2 vs -5.5 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.6 vs -5.4 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
PANSS Marder Positive -1.8 vs -2 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-2.9 vs -2.8 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4 vs -4.1 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.4 vs -5.1 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.3 vs -5.6 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.7 vs -6.1 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.6 vs -6.2 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.78 vs -1.37 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-8.9 vs -6.1 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-5.03 vs -1.37 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-1.3 vs -2 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.8 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.9 vs -4.1 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.5 vs -5.1 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.8 vs -5.6 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.1 vs -6.1 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.8 vs -6.2 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.9 vs -6.1 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Disorganized Thought -0.7 vs -0.7 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-1.4 vs -0.7 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2 vs -1.5 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.1 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.1 vs -2.4 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.5 vs -2.4 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.3 vs -2.7 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.48 vs 0.24 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-4.8 vs -3.4 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-2.85 vs 0.24 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-0.3 vs -0.7 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1 vs -0.7 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.3 vs -1.5 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -2.1 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.4 vs -2.4 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.5 vs -2.4 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.8 vs -2.7 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.3 vs -3.4 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Uncontrolled Hostility/Excitement -0.3 vs -0.5 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-0.5 vs -0.7 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.8 vs -0.9 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.9 vs -1 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.8 vs -1 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.5 vs -1.4 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.8 vs -1.1 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.77 vs 0.86 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-3.8 vs -2.8 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-1.4 vs 0.86 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-0.4 vs -0.5 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.5 vs -0.7 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.9 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.8 vs -1 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.5 vs -1 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.4 vs -1.4 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.1 vs -1.1 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.8 vs -2.8 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Anxiety Depression -1.2 vs -0.9 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-2.2 vs -1.7 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.9 vs -2.5 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3 vs -3.1 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.2 vs -3.4 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.6 vs -3.2 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.4 vs -3 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.55 vs -0.13 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-2.7 vs -1.8 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-1.67 vs -0.13 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.9 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.5 vs -1.7 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.9 vs -2.5 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.1 vs -3.1 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.9 vs -3.4 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3 vs -3.2 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.9 vs -3 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.4 vs -1.8 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
Weight 0.25 kg @ 52wk
absolute change · kg
No placebo or comparator arm
NCT01244828 · Phase 3 · registry result, not featured evidence
BMI 0.07 kg @ 52wk
absolute change · kg
No placebo or comparator arm
NCT01244828 · Phase 3 · registry result, not featured evidence
HbA1c 0% (n=79) @ 52wk
absolute change · percentage points
No placebo or comparator arm
NCT01244828 · Phase 3 · registry result, not featured evidence

+ 23 further endpoints in the CSV export.

Paliperidone (Invega)

SWN-K Total 77.89 score @ 24wk
absolute value · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
SWN-K Total -1.59 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
-2.66 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-0.93 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
SWN-K Mental Functioning -0.14 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
-0.51 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-0.24 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
SWN-K Self Control -0.72 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
-0.62 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-0.29 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
SWN-K Emotional Regulation -0.07 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
0.11 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
0.45 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
SWN-K Physical Functioning -0.11 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
-0.68 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
0.47 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
SWN-K Social Integration -0.55 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
-0.96 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-1.31 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
DAI-10 Total 3.58 score @ 24wk
absolute value · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
DAI-10 Total -0.46 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 3 more results
-0.21 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-1 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
1 score @ 12wk
NCT01577160 · Phase 4 · registry result, not featured evidence
SCL90-R 2.42 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
9.4 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
1.16 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
Krawiecka 0.94 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
1.09 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
1.09 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
PSP -6.5 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 25 more results
-7.23 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-6.28 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-4.289 score @ 2wk
NCT01387542 · Phase 4 · registry result, not featured evidence
-7.053 score @ 6wk
NCT01387542 · Phase 4 · registry result, not featured evidence
-9.868 score @ 10wk
NCT01387542 · Phase 4 · registry result, not featured evidence
59.44 score @ 4wk
NCT00761189 · Phase 4 · registry result, not featured evidence
62.76 score @ 12wk
NCT00761189 · Phase 4 · registry result, not featured evidence
60.27 score @ 4wk
NCT00761189 · Phase 4 · registry result, not featured evidence
64.73 score @ 12wk
NCT00761189 · Phase 4 · registry result, not featured evidence
9.05 score @ 13wk
NCT01362439 · Phase 4 · registry result, not featured evidence
5.7 score @ 4wk
NCT01010776 · Phase 4 · registry result, not featured evidence
8.3 score @ 8wk
NCT01010776 · Phase 4 · registry result, not featured evidence
9.9 score @ 13wk
NCT01010776 · Phase 4 · registry result, not featured evidence
10.4 score @ 26wk
NCT01010776 · Phase 4 · registry result, not featured evidence
68.24 score @ 26wk
NCT01724359 · Phase 4 · registry result, not featured evidence
9.05 score @ 12wk
NCT01577186 · Phase 4 · registry result, not featured evidence
3.4 score @ 24wk
NCT00757705 · Phase 4 · registry result, not featured evidence
14.3 score @ 12wk
NCT01577160 · Phase 4 · registry result, not featured evidence
2.8 score @ 8.86wk
NCT00535145 · Phase 4 · registry result, not featured evidence
6.3 score @ 1wk
NCT00566631 · Phase 3 · registry result, not featured evidence
9.9 score @ 2wk
NCT00566631 · Phase 3 · registry result, not featured evidence
13.8 score @ 4wk
NCT00566631 · Phase 3 · registry result, not featured evidence
16.1 score @ 6wk
NCT00566631 · Phase 3 · registry result, not featured evidence
13.76 score @ 26wk
NCT01662648 · Phase 3 · registry result, not featured evidence
11.14 score @ 26wk
NCT01662648 · Phase 3 · registry result, not featured evidence

+ 58 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asenapine's landscape · Paliperidone (Invega)'s landscape